<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RITONAVIR</span><br/>(ri-ton'a-vir)<br/><span class="topboxtradename">Norvir<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral agent</span>; <span class="classification">protease inhibitor</span><br/><b>Prototype: </b>Saquinavir<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg capsules; 80 mg/mL solution</p>
<h1><a name="action">Actions</a></h1>
<p>HIV protease is an enzyme required to produce the polyprotein procurers of functional proteins in infectious HIV. Protease
         inhibitors prevent cleavage of the viral polyproteins, resulting in the formation of immature noninfectious virus particles.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Protease inhibitor of both HIV-1 and HIV-2 resulting in the formation of noninfectious viral particles.</p>
<h1><a name="uses">Uses</a></h1>
<p>Alone or in combination with other antiretroviral agents or protease inhibitors for treatment of HIV infection. Often used
         to increase the effect of other <small>ANTIRETROVIRALS</small>.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ritonavir; antimicrobial resistance to protease inhibitors; pancreatitis; lactation. Safety and efficacy
         in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B); hepatic diseases, hepatic insufficiency, liver enzyme abnormalities, or hepatitis, jaundice, advanced
         HIV disease; diabetes mellitus, diabetic ketoacidosis, hyperglycemia, hyperlipidemia, hypertriglyceridemia; hemophilia A or
         B, renal insufficiency, concurrent administration with HMG-CoA reductase inhibitors. 
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">HIV</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 600 mg b.i.d. 1 h before or 2 h after meal (may take with a light snack)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>216 y,</i> 400 mg/m<sup>2</sup> b.i.d. (max: 600 mg b.i.d.), start with 250 mg/m<sup>2</sup> b.i.d., increase by 50 mg/m<sup>2</sup> q23d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give preferably with food; oral solution may be mixed with chocolate milk within 1 h of dosing to improve taste.</li>
<li>Do not give concurrently with any of the following drugs: alprazolam, amiodarone, bepridil, bupropion, clozapine, clorazepate,
            diazepam, dihydroergotamine, ergotamine, encainide, estazolam, flecainide, flurazepam, meperidine, midazolam, piroxicam, propafenone,
            propoxyphene, quinidine, rifabutin, triazolam, zolpidem.
         </li>
<li>Store refrigerated at 2°8° C (36°46° F). Protect from light in tightly closed container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Myalgia, allergic reaction, bronchitis, cough, rhinitis, taste alterations, visual disturbances, dysuria, hyperglycemia, diabetes. <span class="typehead">CNS:</span>
<span class="speceff-common">Asthenia,</span> fatigue, headache, fever, malaise, circumoral or peripheral paresthesia, insomnia, dizziness, somnolence, abnormal thinking,
      amnesia, agitation, anxiety, confusion, convulsions, aphasia, ataxia, diplopia, emotional lability, euphoria, hallucinations,
      decreased libido, nervousness, neuralgia, neuropathy, peripheral neuropathy, paralysis, tremor, vertigo. <span class="typehead">CV:</span> Palpitations, vasodilation, hypotension, postural hypotension, syncope, tachycardia. <span class="typehead">Hematologic:</span> Anemia, thrombocytopenia, lymphadenopathy. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, diarrhea, vomiting,</span> abdominal pain, dyspepsia, stomatitis, anorexia, dry mouth, constipation, flatulence, cholecystitis, cholestasis, abnormal
      liver function tests, hepatitis. <span class="typehead">Skin:</span> Rash, sweating, acne, contact dermatitis, pruritus, urticaria, skin ulceration, dry skin. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Carbamazepine,</b>
<b>dexamethasone,</b>
<b>phenobarbital,</b>
<b>phenytoin,</b>
<b>rifabutin,</b>
<b>rifampin,</b> smoking can decrease ritonavir levels. <b>Ritonavir</b> may increase serum levels and toxicity of <b>clarithromycin,</b> especially in patients with renal insufficiency (reduce <b>clarithromycin</b> dose in patients with Cl<sub>cr</sub> desipramine;
      				<b>saquinavir,</b>
<b>amiodarone,</b>
<b>bepridil,</b>
<b>bupropion,</b>
<b>clozapine,</b>
<b>dihydroergotamine,</b>
<b>flecainide,</b>
<b>meperidine,</b>
<b>pimozide,</b>
<b>piroxicam,</b>
<b>propoxyphene,</b>
<b>quinidine,</b>
<b>rifabutin,</b>
<b>trazodone, alfuzosin, fluticasone.</b>
<b> Ritonavir</b> decreases levels of <span class="classification">oral contraceptives</span>, <b>theophylline;</b> may increase <b>ergotamine</b> toxicity with <b>dihydroergotamine,</b>
<b>ergotamine;</b> may increase systemic steroid exposure with<b> fluticasone.</b> Liquid formulation may cause disulfiram-like reaction with <b>alcohol</b> or <b>metronidazole.</b> See the complete prescribing information for a comprehensive table of potential, but not studied, drug interactions. <span class="typehead">Herbal:</span>
<b>St. John's wort, garlic</b> may decrease <span class="classification">antiretroviral</span> activity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Peak:</span> 24 h. <span class="typehead">Distribution:</span> 9899% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver by cytochrome P4503A4 (CYP3A4). <span class="typehead">Elimination:</span> Excreted primarily in feces (&gt;80%). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor periodically CBC with differential and platelet count, liver function, kidney function, serum albumin,
            lipid profile, CPK, serum amylase, electrolytes, blood glucose HbA1c, and alkaline phosphatase.
         </li>
<li>Withhold drug and notify physician in the presence of abnormal liver function.</li>
<li>Assess for S&amp;S of GI distress, peripheral neuropathy, and other potential adverse effects.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn potential adverse reactions and drug interactions; report to physician use of any OTC or prescription drugs.</li>
<li>Do not breast feed while taking this drug.</li>
<li>Take this drug exactly as prescribed. Do not skip doses. Take at same time each day.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>